Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
DUBLIN, Ireland, March 01, 2016 -- SIGMOID PHARMA LIMITED, a privately-owned, specialty pharmaceutical company developing innovative therapeutics for gastrointestinal and immunological diseases using its proprietary SmPill® solid oral delivery system, announced today that Dr. Ivan Coulter, Chief Executive Officer, will provide a corporate update at the 36th Annual Cowen & Co. Healthcare Conference, taking place in Boston, Massachusetts March 7-9, 2016.
| Presentation Details: | |
| Title: | 36th Annual Cowen & Company Healthcare Conference |
| Date: | March 9th |
| Time: | 10:30am Eastern Time |
| Location: | MIT Room, The Marriott Copley Hotel, Boston. |
About Sigmoid Pharma
Sigmoid Pharma is a specialty pharmaceutical company developing innovative therapeutics for gastrointestinal and immunological diseases. The Company’s Single-Multiple Pill (SmPill®) technology is a versatile delivery system for optimising the formulation of active therapeutic agents and allowing targeted release at the site of disease. Sigmoid’s lead program is CyCol®, a colon-targeted, formulation of cyclosporine that permits local, topical exposure of a powerful immunosuppressant whilst minimizing systemic blood levels, thus offering the potential for an efficacious and safe oral treatment of moderate-severe ulcerative colitis (UC). Another pipeline product is has received US FDA Orphan Designation for Graft-versus-Host Disease. For additional information please visit: http://www.sigmoidpharma.com
For further information contact: Leo Toole Chief Financial Officer Sigmoid Pharma Ltd, Blocks 9/10 Nexus UCD, Belfield Office Park, Beech Hill Road, Dublin 4, D04 V2N9, Ireland. Phone +353 (0) 1 700 7452 E-mail: [email protected] US Investors: Andrew McDonald Ph.D. LifeSci Advisors LLC [email protected]
